This time-resolved analysis suggests that early seizure control is primarily influenced by surgical and tumor burden-related factors, whereas long-term seizure outcomes and recurrence appear to be predominantly determined by the clinical presentation at diagnosis rather than treatment-related variables.
Abstract
Objective
Given the reciprocal interaction between tumor biology and seizure activity, seizure outcomes in low-grade glioma (LGG) may be dynamic and influenced by both tumor- and treatment-related factors. We aimed to identify factors associated with seizure occurrence across distinct clinical stages, including diagnosis, surgery, long-term follow-up, and antiseizure medication (ASM) withdrawal.
Methods
We retrospectively analyzed patients with World Health Organization grade 1-2 glioma who underwent surgery between January 2001 and February 2025 and experienced seizures during their disease course. Clinical, radiological, molecular, and treatment-related variables, along with longitudinal seizure data, were collected. Seizure outcomes were evaluated at 6 and 12 months and at final follow-up, including time to postoperative seizure recurrence and recurrence after ASM withdrawal.
Results
Among 100 patients (mean postoperative follow-up = 89.9 months), 70.0% achieved seizure freedom during the final year of follow-up. At 6 months, gross total resection (odds ratio [OR] = 3.45, 95% confidence interval [CI] = 1.19-10.01, p = .02) and preoperative tumor volume (OR = .99, 95% CI = .97-1.00, p = .048) were independently associated with seizure outcomes. At 12 months, preoperative tumor volume (OR = .99, 95% CI = .98-1.00, p = .04) was significant. Conversely, seizure at presentation was the sole independent determinant of favorable long-term seizure outcome (OR = 6.37, 95% CI = 2.07-19.61, p < .01) and the only predictor of reduced postoperative seizure recurrence in survival analysis (hazard ratio = .26, 95% CI = .11-.62, p < .01). ASM withdrawal was successful in 67.7%. Although tumor progression showed a trend toward an association with recurrence in univariate analyses, no independent predictors were identified in Cox regression for ASM withdrawal outcomes.
Significance
This time-resolved analysis suggests that early seizure control is primarily influenced by surgical and tumor burden-related factors, whereas long-term seizure outcomes and recurrence appear to be predominantly determined by the clinical presentation at diagnosis rather than treatment-related variables. These findings suggest that postoperative seizure prognosis in LGG reflects pre-existing epileptogenic vulnerability and may not be adequately captured by single time point assessments.
It is found that the association between early epilepsy surgery and seizure reduction in palliative procedures reflects the heterogeneity of the population, including different types of surgical procedures and lesional and nonlesional epilepsies.
Robert M Crutcher, David E. Horvat, A. Caraway et al.· Epilepsia· 0 citations
Postoperative ASM reduction was associated with domain-specific cognitive improvement following ATL, particularly in WM, which support ASM tapering as a potentially modifiable factor influencing postoperative cognitive outcomes.
Kazushi Ukishiro, S. Osawa, M. Ogawa et al.· Epilepsia· 0 citations
High-frequency IEDs on early postoperative EEG may identify patients at increased risk of long-term deterioration after surgery for HS-related TLE, and prospective studies are needed before modifying routine follow-up strategies.
Kate Durbano, Q. Calonge, V. Frazzini et al.· Seizure· 0 citations
The model achieved high specificity in predicting long-term seizure recurrence, which supports its potential clinical utility for postoperative risk stratification and counseling rather than surgical exclusion and underscores the translational potential of network-level biomarkers to complement conventional predictors.
V.Yu. Karpychev, Rebecca W. Roth, William Yun et al.· Neurology· 0 citations
BACKGROUND
Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, is increasingly used in tuberous sclerosis complex (TSC)-associated epilepsy; however, long-term real-world outcomes and factors associated with favorable response remain unclear. This study aimed to evaluate the long-term seizure outcomes of adjunctive everolimus and explore clinical factors associated with treatment response.
METHODS
We retrospectively recruited 21 patients with active TSC-associated epilepsy receiving adjunctive everolimus and assessed seizure outcomes during follow-up. Clinical characteristics were compared between responders and non-responders at 1 year after treatment initiation.
RESULTS
Over a median treatment duration of 72 months, responder rates ranged from 53.8% to 64.7%, and seizure-free rates ranged from 33.3% to 41.2%. Responders had fewer involved organ systems at baseline (median 3 vs. 4, p = 0.020) and lower anti-seizure medication burden (median 2 vs. 4, p = 0.045). Younger age at treatment initiation showed a trend toward improved response.
CONCLUSION
Adjunctive everolimus was associated with sustained long-term seizure reduction in this real-world cohort. In exploratory analyses, fewer involved organ systems and fewer baseline ASMs were associated with favorable treatment response. These findings require validation in larger prospective cohorts.
Unknown authors· Journal of the Formosan Medi...· 0 citations
Temporary neurological deterioration following glioma surgery does not appear to adversely influence overall or progression-free survival, regardless of IDH status, however, persistent postoperative deficits, as well as newly acquired deficits that remain evident during follow-up, are strong indicators of an unfavorable prognosis in patients with IDH-wild-type gliomas.
J. Klingenschmid, M. Demetz, N. Pichler et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.